What if a single antibody could do the job of two drugs — reawakening exhausted T cells and dismantling a tumor's defensive blood supply in one coordinated strike? Bispecific antibodies are rewriting the rules of cancer immunotherapy, engineered to hit two targets at once instead of relying on chance combinations of separate treatments. In this 5-minute overview, we break down exactly how these dual-targeting molecules work, using three real-world examples (CD370/PD-L1, PD-1/VEGF-A, and PD-L1/VEGFR2) to show how researchers are turning "cold," immune-invisible tumors into ones the immune system can actually see and attack. Along the way, we'll trace the path from already-approved bispecific therapies to the wave of next-generation candidates now in clinical trials and reveal the practical advantages that make one engineered molecule more powerful than two separate antibodies combined. Whether you're a researcher designing your next immuno-oncology study or a student trying to make sense of where cancer therapeutics are headed, this is the mechanism you need to understand.
Contact an expert for detailed support.
